Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16445181 | 0.93 | EPHX2 (0.46) | APPEPHX2PTGS1PDE4ALMNA | |
| SCHEMBL7082515 | 0.91 | EPHX2 (0.49) | APPEPHX2PTGS1PDE4ALMNA | |
| SCHEMBL3724090 | 0.85 | — | — | |
| SCHEMBL10596261 | 0.85 | APP (0.50) | APPEPHX2PTGS1PDE4ALMNA | |
| SCHEMBL16446001 | 0.84 | EPHX2 (0.42) | APPEPHX2PTGS1PDE4ALMNA | |
| SCHEMBL11061814 | 0.82 | EPHX2 (0.53) | APPEPHX2 | |
| SCHEMBL7026742 | 0.80 | EPHX2 (0.56) | EPHX2 | |
| SCHEMBL21485088 | 0.80 | EPHX2 (0.56) | EPHX2 | |
| SCHEMBL28382453 | 0.80 | EPHX2 (0.56) | EPHX2 | |
| SCHEMBL4076228 | 0.79 | EPHX2 (0.50) | APPEPHX2PTGS1LMNABLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240009151-A1 | FORMULATIONS OF AZOBENZENE PHOTOREACTIVE COMPOUNDS | BAYON THERAPEUTICS, INC. | 2024-01-11 | — | — | US | disclosed |
| US-20230357451-A1 | ALKYLATED CYCLODEXTRIN COMPOSITIONS AND PROCESSES FOR PREPARING AND USING THE SAME | CYDEX PHARMACEUTICALS INC (US) | 2023-11-09 | — | — | US | disclosed |
| US-11795241-B2 | Fractionated alkylated cyclodextrin compositions and processes for preparing and using the same | CYDEX PHARMACEUTICALS, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20230255919-A1 | COMPOSITION CONTAINING CYCLODEXTRIN AND BUSULFAN | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2023-08-17 | — | — | US | disclosed |
| EP-3183295-B1 | FRACTIONATED ALKYLATED CYCLODEXTRIN COMPOSITIONS AND PROCESSES FOR PREPARING AND USING THE SAME | CYDEX PHARMACEUTICALS INC (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20230002513-A1 | ALKYLATED CYCLODEXTRIN COMPOSITIONS AND PROCESSES FOR PREPARING AND USING THE SAME | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2023-01-05 | — | — | US | disclosed |
| EP-4083075-A1 | MANUFACTURING PROCESS FOR CYCLODEXTRIN DERIVATIVES | CyDex Pharmaceuticals, Inc. (US) | 2022-11-02 | — | — | EP | disclosed |
| EP-3702374-B1 | MANUFACTURING PROCESS FOR CYCLODEXTRIN DERIVATIVES | CYDEX PHARMACEUTICALS INC (US) | 2022-03-23 | — | — | EP | disclosed |
| US-11208500-B2 | Manufacturing process for cyclodextrin derivatives | CYDEX PHARMACEUTICALS, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-20210147582-A1 | FRACTIONATED ALKYLATED CYCLODEXTRIN COMPOSITIONS AND PROCESSES FOR PREPARING AND USING THE SAME | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2021-05-20 | — | — | US | disclosed |
| US-20180051098-A1 | MANUFACTURING PROCESS FOR CYCLODEXTRIN DERIVATIVES | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2018-02-22 | — | — | US | disclosed |
| US-20170275388-A1 | FRACTIONATED ALKYLATED CYCLODEXTRIN COMPOSITIONS AND PROCESSES FOR PREPARING AND USING THE SAME | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2017-09-28 | — | — | US | disclosed |
| US-9751957-B2 | Manufacturing process for cyclodextrin derivatives | CYDEX PHARMACEUTICALS, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20170158781-A1 | ALKYLATED CYCLODEXTRIN COMPOSITIONS AND PROCESSES FOR PREPARING AND USING THE SAME | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2017-06-08 | — | — | US | disclosed |
| US-9493582-B2 | Alkylated cyclodextrin compositions and processes for preparing and using the same | CYDEX PHARMACEUTICALS, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-20160009826-A1 | MANUFACTURING PROCESS FOR CYCLODEXTRIN DERIVATIVES | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2016-01-14 | — | — | US | disclosed |
| US-20150284479-A1 | ALKYLATED CYCLODEXTRIN COMPOSITIONS AND PROCESSES FOR PREPARING AND USING THE SAME | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2015-10-08 | — | — | US | disclosed |
| US-20150045311-A1 | ALKYLATED CYCLODEXTRIN COMPOSITIONS AND PROCESSES FOR PREPARING AND USING THE SAME | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2015-02-12 | — | — | US | disclosed |
| US-5153112-A | Containing cyanine dye and anionic surfactant | KONICA CORPORATION (JP) | 1992-10-06 | — | — | US | disclosed |
| EP-0494121-A1 | Silver halide photographic light sensitive material | KONICA CORPORATION (JP) | 1992-07-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284479-A1 | ALKYLATED CYCLODEXTRIN COMPOSITIONS AND PROCESSES FOR PREPARING AND USING THE SAME | AGL, AGPS, MGAM | APP 630/4885EPHX2 1314/4885PTGS1 3552/4885 |
| US-20170275388-A1 | FRACTIONATED ALKYLATED CYCLODEXTRIN COMPOSITIONS AND PROCESSES FOR PREPARING AND USING THE SAME | ALG1, DDOST, AGPS | APP 292/4885EPHX2 439/4885PTGS1 3302/4885 |
| US-11795241-B2 | Fractionated alkylated cyclodextrin compositions and processes for preparing and using the same | AGPS, DDOST, ALG1 | APP 377/4885EPHX2 481/4885PTGS1 4046/4885 |
| US-20170158781-A1 | ALKYLATED CYCLODEXTRIN COMPOSITIONS AND PROCESSES FOR PREPARING AND USING THE SAME | AGL, AGPS, MGAM | APP 630/4885EPHX2 1314/4885PTGS1 3552/4885 |
| US-20210147582-A1 | FRACTIONATED ALKYLATED CYCLODEXTRIN COMPOSITIONS AND PROCESSES FOR PREPARING AND USING THE SAME | AGPS, DDOST, ALG1 | APP 377/4885EPHX2 481/4885PTGS1 4046/4885 |
| US-20150045311-A1 | ALKYLATED CYCLODEXTRIN COMPOSITIONS AND PROCESSES FOR PREPARING AND USING THE SAME | AGL, AGPS, MGAM | APP 630/4885EPHX2 1314/4885PTGS1 3552/4885 |
| US-20230255919-A1 | COMPOSITION CONTAINING CYCLODEXTRIN AND BUSULFAN | SBDS, HBG1, CD99 | APP 3227/4885EPHX2 3341/4885PTGS1 3136/4885 |
| US-11208500-B2 | Manufacturing process for cyclodextrin derivatives | DCXR, AGL, OSTC | APP 152/4885EPHX2 2250/4885PTGS1 3468/4885 |
| US-20240009151-A1 | FORMULATIONS OF AZOBENZENE PHOTOREACTIVE COMPOUNDS | CRY1, PDE6C, PDE6D | APP 954/4885EPHX2 2396/4885PTGS1 2539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.